Nexus6 asthma monitoring technology

Auckland-based medical device company Nexus6 has secured $3m from Australia-based life sciences investment firm BioScience Managers. Details can be found here.. http://medicaldevices-business-review.com...asthma-monitoring-technology
Source: Cystic Fibrosis Asthma, Allergies and Green Forum - Category: Respiratory Medicine Authors: Tags: Asthma, Allergies and Green Source Type: forums

Related Links:

We present a 23-year-old male with a history of cystic fibrosis (CF) with associated renal disease, bronchiectasis, pneumothorax, and distal intestinal obstruction syndrome admitted for CF exacerbation. Sputum culture was positive for methicillin resistant Staphylococcus aureus (MRSA). Chest imaging revealed extensive opacities in the left lung. His FEV1 during admission was 52% (baseline 70%). Allergy was consulted as inhaled vancomycin therapy was preferred, but the patient had previous vancomycin-induced reactions.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
High antibiotic utilization is an essential element of life-saving care for cystic fibrosis (CF) patients. However, adverse drug reactions (ADRs) to antibiotics occur more commonly and discrete types of ADRs may differ in CF patients compared to the general population. Characterization of documented ADRs among CF patients is needed in order understand how antibiotic utilization can be improved for CF patients.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF), representing a significant clinical challenge. It is especially a concern in the pediatric population given adverse effects of steroids in this population. Here we report on the use of omalizumab in the treatment of steroid-resistant ABPA in a pediatric patient with CF.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
BackgroundChronic rhinosinusitis (CRS) is associated with bronchiectasis; however, this relationship has not been well studied in the United States (US) population. In this work we aimed to determine the prevalence of CRS among patients with bronchiectasis affiliated with a US tertiary medical center and identify which comorbid diseases are associated with the presence of CRS in patients with bronchiectasis.MethodsThis was a retrospective cohort study in which data were obtained from a large database warehouse at a tertiary care center. Patients with bronchiectasis were identified from 2007 to 2017 using diagnosis codes fr...
Source: International Forum of Allergy and Rhinology - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
This study assessed omalizumab outcomes in real-world patients with allergic asthma stratified by pretreatment biomarker levels. METHODS: Patients with allergic asthma aged ≥12 years initiated on omalizumab with ≥12 months of data after index were identified in the Allergy Partners electronic medical records (2007-2018). Patients with ≥1 diagnosis of chronic obstructive pulmonary disease in combination with ≥10 pack-years of smoking, cystic fibrosis, Alpha-1 antitrypsin deficiency, bronchiectasis, interstitial lung disease, and sarcoidosis in the 12 months before or after index were excluded. Patients were...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Ther Source Type: research
Polymyxins, namely colistimethate sodium (colistin or polymyxin E) and polymyxin B, are used for multi-drug resistant gram-negative bacterial infections, including Pseudomonas aeruginosa and Acinetobacter baumannii 1. As treatments and therapy have advanced, patients with cystic fibrosis are living longer. However, these patients have high exposure to intravenous antibiotics, most commonly penicillins, cephalosporins, and aminoglycosides. With colonization or infections with resistant gram-negative bacilli, the exposure to antibiotics broadens to include the polymyxins.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research
The type I receptor for advanced glycation end-products (RAGE) belongs to the immunoglobulin superfamily and is abundantly expressed in the lungs, notably in type 1 alveolar epithelial cells.1 As such, RAGE has been implicated in lung development and in the pathogenesis of chronic lung diseases ranging from cystic fibrosis to asthma.1
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research
Publication date: May–June 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 5Author(s): Richard H. Stanford, Carlyne Averell, Emily D. Parker, Cori Blauer-Peterson, Tyler K. Reinsch, Ami R. BuikemaBackgroundAlthough efficacy and safety of fluticasone furoate/vilanterol (FF/VI) and budesonide/formoterol (BUD/F) have been demonstrated in clinical studies, real-world comparisons of utilization have not been performed.ObjectiveTo compare similar patients with asthma initiating FF/VI or BUD/F on measures of adherence, persistence, and the asthma medication ratio (AMR).MethodsThis wa...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
In this study, we exposed apically well-differentiated human NECs cultured at the ALI to the related flaviviruses ZIKV, JEV, WNV, and Usutu virus (USUV). We selected these viruses due to the recent increasing evidences of potential threat to humans (Cadar et al., 2017; Simonin et al., 2018). We show that NECs are particularly susceptible to JEV and WNV infection and to other flaviviruses included in this study. Infection with each virus led to shedding of infectious virus particles through the apical and basolateral surfaces and triggered host mechanisms at the level of inflammatory and antiviral mediators. Given...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
In this study we found blocking autophagy led to increased CP growth in both macrophages and mouse embryonic fibroblasts. In vivo, loss of the autophagy elongation component ATG16L1 specifically in myeloid cells led to increased mortality in response to CP infection, characterized by greater numbers of neutrophils and dendritic cells, but no change in the CP burden in the lungs. This was accompanied by an increase in inflammasome-active macrophages and IL-1β production. While induction of autophagy in macrophages led to reduced CP growth in vitro, in vivo treatment with rapamycin led to increased mortality of infected...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Cystic Fibrosis | Medical Devices | Respiratory Medicine